People: Allergan Inc (AGN.N)

AGN.N on New York Stock Exchange

184.21USD
24 Oct 2014
Price Change (% chg)

$0.84 (+0.46%)
Prev Close
$183.37
Open
$183.77
Day's High
$186.85
Day's Low
$183.40
Volume
251,989
Avg. Vol
300,150
52-wk High
$192.60
52-wk Low
$88.34

Search Stocks

Jones, Trevor 

Brief Biography

Dr. Professor Trevor M. Jones, Ph.D., CBE, is Independent Director of Allergan Inc. He served as the Director General of the Association of the British Pharmaceutical Industry, an association representing the interests of approximately 75 British and international pharmaceutical companies, from 1994 through his retirement in August 2004. From 1987 to 1994, Prof. Jones was a director at Wellcome plc.Prof. Jones received his bachelor of pharmacy degree and Ph.D. from the University of London and is currently a visiting professor at King’s College London. He has also gained an honorary doctorate from the University of Athens as well as honorary doctorates in science from the Universities of Strathclyde, Nottingham, Bath and Bradford in the United Kingdom. Prof. Jones was recognized in the Queen’s Honors List and holds the title of Commander of the British Empire. He is also a fellow of the Royal Society of Chemistry, a fellow of the Royal Society of Medicine, a fellow of the Royal Pharmaceutical Society, an honorary fellow of the Royal College of Physicians and of its Faculty of Pharmaceutical Medicine and an honorary fellow of the British Pharmacological Society. Prof. Jones is a board member of Synexus Ltd., Sigma-Tau Finanziaria S.p.A., and Verona Pharma plc, a public biotechnology company dedicated to research in respiratory diseases. Prof. Jones is President and a former board member of Sigma-Tau Pharmaceuticals Inc. Prof. Jones is a founder of the Geneva-based public-private partnership, Medicines for Malaria Venture and a founder and board member of the UK Stem Cell Foundation. Prof. Jones is a former Chairman of the boards of ReNeuron Group plc and Synexus Ltd. Prof. Jones is also a former member of the boards of NextPharma Technologies Holdings Ltd., Sigma-Tau Industrie Farmaceutiche Riunite S.p.A, ReNeuron Group plc, and Tecnogen S.p.A. Prof. Jones was appointed to Board in July 2004 and is a member of the Corporate Governance and Compliance Committee and the Science & Technology Committee.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Pyott

12,029,300

Douglas Ingram

3,576,040

James Hindman

--

Scott Whitcup

2,913,090

Arnold Pinkston

--

Scott Sherman

--
As Of 30 Dec 2013
Search Stocks